Alexandria Venture Investments

Founded 1996


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 141
Average round size
The average size of a deal this fund participated in
Portfolio companies 122
Rounds per year 5.64
Lead investments 7
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 23
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science

We also calculated 3 valuable employees in our database.

The higher amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points less often commits exit comparing to other companies. The fund is constantly included in 25-48 investment rounds annually. Opposing the other organizations, this Alexandria Venture Investments works on 17 percentage points less the average amount of lead investments. The typical startup value when the investment from Alexandria Venture Investments is more than 1 billion dollars. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top activity for fund was in 2018.

The usual cause for the fund is to invest in rounds with 7 partakers. Despite the Alexandria Venture Investments, startups are often financed by ARCH Venture Partners, 5AM Ventures, Alexandria Real Estate Equities. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, OrbiMed, 5AM Ventures. In the next rounds fund is usually obtained by Tim Disney, The Duke of Bedford, Illumina Ventures.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Biotechnology, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, Epic Sciences, Codiak Biosciences.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Fountain Therapeutics

Health Care
$15M18 Nov 2021 San Francisco, California, United States

Disc Medicine

Health Care
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Asher Bio

$108M01 Sep 2021 San Francisco, California, United States

LQT Therapeutics

$19M10 Aug 2021 Laval, Quebec, Canada

Deep Genomics

Artificial Intelligence
$180M28 Jul 2021 Old Toronto, Ontario, Canada


$25M27 Jul 2021 San Francisco, California, United States


$5M14 Jul 2021 Cambridge, Massachusetts, United States

TRex Bio

$59M22 Jun 2021 South San Francisco, California, United States

Mnemo Therapeutics

$88M16 Jun 2021 Paris, Ile-de-France, France
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

– ROME Therapeutics announced the completion of a $77m Series B financing round.
– The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
– ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
– ROME has identified multiple repeatome-derived targets and created an internal data science platform, called repeatomics, to analyze vast quantities of data available through the repeatome.

Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Alexandria Venture Investments?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: